H.C. Wainwright raised the firm’s price target on ADMA Biologics to $6 from $5 and keeps a Buy rating on the shares. The company reported fiscal 2024 guidance with strong growth expected in 2024, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ADMA:
- ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
- ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older
- ADMA Biologics announces FDA approval of BIVIGAM in pediatric patient setting
- ADMA Biologics receives FDA approval for tenth plasma collection cent er
- ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
